Cronex크로넥스

Cronex is a small KONEX-listed xenotransplant and minipig research firm with no reported financials in the data and a sharp share-price decline over the past year.

Cronex develops genetically edited pig technology for possible organ transplants, breeds Jeju minipigs for drug testing and research, and runs a contract research business. The data includes no annual or trailing financial statements, no valuation multiples and no news headlines, so the current state of revenue and profitability cannot be assessed from this pack. The share price closed at ₩649 with a market value of about ₩4.3B, well below its 52-week high of ₩2,300.

What stands out

• No annual or trailing financial results are included in the data, so revenue, profit and cash position are unknown here.
• The shares returned -34.8% over one year and -18.9% over three months, though they are up 8.2% over one month.
• Filings over the past few months include a rights offering decision, a convertible bond issue and its amendment, a conversion price adjustment, and stock purchase option grants.
• A material matters report on an acquisition of equity securities in another company was amended on 2026-09-30.
• No foreign or institutional net flows were recorded over the last 20 days, and foreign ownership is 0%.

What to watch

• Whether the rights offering and convertible bonds proceed, since they could add shares and affect per-share value.
• Details of the equity acquisition that was amended on 2026-09-30, which are not in the data.
• Any upcoming financial statements, which the data does not yet show; liquidity and dilution risk for a small KONEX stock.